Britain and America have concluded a important bilateral deal that will keep no tariffs on British pharmaceutical products entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to boost spending on medicines through the NHS. This commitment secures that import taxes on these vital exports will remain at zero for a timeframe of the next three years.
This development is in response to recent warnings to dramatically increase tariffs on patented pharmaceutical products, with increases discussed as high as one hundred percent.
"This agreement with the Britain strengthens the worldwide climate for cutting-edge drugs and brings long-overdue balance to American-British medicine commerce," a statement said.
Economic Impact
Pharmaceuticals constitute one of the UK's biggest exports to the America, which is clearly the largest market for leading UK drugmakers.
Statistics show that in the 12 months to the end of the third quarter, the UK exported drugs worth £11.1bn to the US. This figure made up a significant portion of total UK exports in that period.
"This deal safeguards employment, stimulates investment and facilitates the UK to become a global hub for biotech and pharma," a minister remarked.
Key British Pledges
The agreement entails several notable changes from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a aim to double total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be limited at 15%. Last year, rebates topped twenty percent.
Industry Background
The pact takes place against a protracted tension between the drug companies and the UK government over medicine costs and regulatory access.
The disagreement were heightened by arguments that American consumers were paying several times more for the identical medicines than patients in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar investments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS must spend more on medicines, noting that its budget allocation on drugs had declined as a proportion of its resources over the last ten years.
